Quantcast
Last updated on April 16, 2014 at 8:29 EDT

Latest GlaxoSmithKline Stories

2013-11-01 08:27:46

NEW YORK, Nov. 1, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-10-30 23:34:03

MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: Asthma Therapeutics Market to 2019; http://www.marketresearch.com/land/product.asp?productid=7840710&progid=85830. Rockville, MD (PRWEB) October 30, 2013 Asthma Therapeutics Market to 2019 The asthma market is forecast to grow marginally to 2019 across the leading eight developed nations, from $16.6 billion in 2012 to a projected value of $21.6 billion in 2019. This...

2013-10-30 12:25:42

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta(2)-agonist (LABA),...

2013-10-27 23:02:48

RnRMarketResearch.com adds latest report on “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Greece” to its store. Dallas, TX (PRWEB) October 27, 2013 The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Greece. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure. Most importantly, the...

2013-10-23 08:29:42

LONDON, October 23, 2013 /PRNewswire/ -- Global healthcare company GSK reported Q3 results showing group sales growth +1%, earnings per share +16% and strong cash generation which has enabled the company to re-affirm its guidance for the full year. In a video interview, CFO Simon Dingemans said the company was making good progress on reshaping and restructuring its cost base and that GSK was now seeing the benefit of savings in both in its operations and the transformed...

2013-10-21 08:25:51

DENVER, Oct. 21, 2013 /PRNewswire/ --MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, today announced that Sydney Rollock has joined the company as Chief Marketing Officer. In this role, Rollock will oversee global brand management, global marketing and sales, as well as help lead MusclePharm's corporate strategy to ultimately grow product lines and revenue streams. (Photo: http://photos.prnewswire.com/prnh/20130715/LA46954LOGO)...

World's First Malaria Vaccine Could Save Millions Of Lives
2013-10-08 11:00:43

Brett Smith for redOrbit.com - Your Universe Online GlaxoSmithKline (GSK) is expected to seek regulatory approval for a malaria vaccine that recently delivered promising results in a large-scale trial conducted across Africa. The new vaccine – dubbed RTS,S – would be the world’s first malaria vaccine and could significantly boost public health in parts of Africa where malaria runs rampant. "In Africa we experience nearly 600,000 deaths annually from malaria, mainly children...

2013-10-07 08:24:46

CARLSBAD, Calif., Oct. 7, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that GlaxoSmithKline (GSK) has added a development candidate ISIS-GSK3(Rx), to its collaboration with Isis. Isis earned $7 million in milestone payments associated with the advancement of this program. ISIS-GSK3(Rx) is an antisense drug designed to inhibit the production of an undisclosed target to treat a common viral infection. Isis will develop ISIS-GSK3(Rx) to Phase 2...

2013-10-03 16:23:39

SCRS Global Impact Partner Program Welcomes: DrugDev, EMD Serono, Forte Research Systems, GlaxoSmithKline, HealthCarePoint, IntegReview IRB, Janssen, Merge Healthcare, Pfizer, Quintiles. ROCKVILLE, Md., Oct. 3, 2013 /PRNewswire/ -- New organizations representing sponsors, CROs, and clinical service providers continue to join the SCRS' Global Impact Partner (GIP) program. SCRS will host the first GIP Board meeting at the upcoming 2013 Site Solutions Summit. Since launching the GIP...

2013-10-02 23:04:21

On September 19, US District Judge ordered a Paxil birth defects lawsuit be transferred to Philadelphia Court of Common Pleas. In light of this news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by alleged Paxil side effects. San Diego, CA (PRWEB) October 02, 2013 AttorneyOne.com, a recognized authority on law, updated the website recently and they are now actively...